Beta Drugs (NSE:BETA) Debt-to-Equity : 0.07 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Beta Drugs Debt-to-Equity?

Beta Drugs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹50 Mil. Beta Drugs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹60 Mil. Beta Drugs's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹1,571 Mil. Beta Drugs's debt to equity for the quarter that ended in Mar. 2024 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Beta Drugs's Debt-to-Equity or its related term are showing as below:

NSE:BETA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.33 Max: 4.47
Current: 0.07

During the past 12 years, the highest Debt-to-Equity Ratio of Beta Drugs was 4.47. The lowest was 0.07. And the median was 0.33.

NSE:BETA's Debt-to-Equity is ranked better than
76.98% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs NSE:BETA: 0.07

Beta Drugs Debt-to-Equity Historical Data

The historical data trend for Beta Drugs's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beta Drugs Debt-to-Equity Chart

Beta Drugs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Equity

Get a 7-Day Free Trial

0.40

0.26

0.22

0.17

0.07

Beta Drugs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial														0.22	0.15	0.17	0.11	0.07

Competitive Comparison of Beta Drugs's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Drugs's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Debt-to-Equity falls into.

Beta Drugs Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Beta Drugs's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(49.574	+	60.407)	/	1571.169
	=	0.07

Beta Drugs's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(49.574	+	60.407)	/	1571.169
	=	0.07

Beta Drugs (NSE:BETA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Beta Drugs Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Beta Drugs's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Beta Drugs (NSE:BETA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beta Drugs Ltd (NSE:BETA) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114

Website

https://www.betadrugslimited.com

Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports it to other countries of which key revenue is derived from the sales made in India.

Beta Drugs (NSE:BETA) Headlines

No Headlines